Compare DOV & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOV | KVUE |
|---|---|---|
| Founded | 1947 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Specialty Chemicals |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.5B | 33.1B |
| IPO Year | N/A | 2023 |
| Metric | DOV | KVUE |
|---|---|---|
| Price | $230.42 | $18.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 12 |
| Target Price | ★ $223.20 | $19.58 |
| AVG Volume (30 Days) | 1.6M | ★ 62.2M |
| Earning Date | 01-29-2026 | 02-17-2026 |
| Dividend Yield | 0.90% | ★ 4.44% |
| EPS Growth | N/A | ★ 35.31 |
| EPS | ★ 7.94 | 0.75 |
| Revenue | $8,092,571,000.00 | ★ $15,006,000,000.00 |
| Revenue This Year | $6.78 | N/A |
| Revenue Next Year | $4.48 | $2.72 |
| P/E Ratio | $29.06 | ★ $25.01 |
| Revenue Growth | ★ 4.47 | N/A |
| 52 Week Low | $143.04 | $14.02 |
| 52 Week High | $237.54 | $25.17 |
| Indicator | DOV | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 73.80 | 74.77 |
| Support Level | $197.97 | $17.96 |
| Resistance Level | $237.54 | $18.97 |
| Average True Range (ATR) | 5.74 | 0.37 |
| MACD | 1.95 | 0.10 |
| Stochastic Oscillator | 85.06 | 85.29 |
Founded in 1955 by George Ohrstrom, Dover has become an industrial behemoth through the acquisition of dozens of esteemed brands. The company is organized into five segments through which it designs and manufactures highly engineered components, such as vehicle repair, factory automation, welding, aerospace, fuel dispensing, printing, liquid handling, refrigeration, and can-making equipment. It has operations around the globe but generates over half of its revenue in the United States.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.